Special Issue "Cancer Vaccines and Immunotherapy"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 May 2011).
Interests: design of HPV immunotherapeutics; developing new and effective therapies for cervical cancer; prostate cancer and melanoma
Interests: tumor immunology, developing therapeutic and preventive tumor vaccine; ovarian cancer, multiple myeloma, breast cancer, prostate cancer
Special Issues and Collections in MDPI journals
Despite intense ongoing research, many cancers are still incurable. Tumor cells induce immune tolerance, which represents a major obstacle for the application of cancer immunotherapy. Therefore, a current challenge for the field of cancer immunotherapy is to develop new approaches capable of breaking tumor-induced tolerance and inducing the (re-)activation of spontaneous and/or vaccine-triggered anti-tumor immune responses.
The exciting news this year is that we are now experiencing that cancer immunotherapy is finally becoming part of FDA approved cancer therapies. Cancer immunotherapy may provide a more effective and safer alternative approach to standard treatments, since unlike these currently available standard treatments, vaccines exploit natural anti-tumor immune surveillance, and offer the potential to provide durable control of primary and metastatic cancers.
Therefore, we invite research and review manuscripts in the field of cancer vaccines/cancer immunotherapy and topics related to new tumor antigen discovery, novel developments in therapeutic and preventive cancer vaccines, T regulatory cells, dendritic cell vaccines, T cell vaccines, B cell vaccines, pharmacological therapy, gene therapy, tumor-associated cancer testis antigens, immunosuppressive mechanisms, immune-regulatory applications and the regulation of immune surveillance against cancer as well as multi modality cancer approaches in which cancer vaccines/cancer immunotherapies play a role.
We are looking forward to your vital contributions.
Dr. W. Martin Kast
Dr. Maurizio Chiriva Internati
- cytotoxic T lymphocytes
- dendritic cells
- therapeutic cancer vaccines
- preventive cancer vaccines
- cancer immunotherapy